Several healthcare and life sciences names posted notable gains in after-hours trading, driven by clinical updates, earnings releases, and in some cases, unexplained momentum.
Tectonic Therapeutic Inc. (TECX) surged 30.93% in the overnight session, climbing from $18.62 at the close to $24.38 by late evening. The sharp move followed the company's announcement of positive topline results from its Phase 1b Part B trial of TX45, a long-acting Fc-relaxin fusion protein. The therapy, tested in patients with Group 2 pulmonary hypertension with heart failure and reduced ejection fraction (PH-HFrEF), demonstrated both tolerability and improvements in left heart function and pulmonary hemodynamics after a single intravenous dose.
Glaukos Corp. (GKOS) advanced 15.45% after hours, rising from $77.09 to $89.00. The company reported third-quarter net sales of $133.5 million, up 38% year-over-year. While it posted a net loss of $16.2 million, the figure marked an improvement from the $21.4 million loss in the same quarter last year. Glaukos also provided updated guidance, projecting 2025 revenue between $490 million and $495 million, and preliminary 2026 revenue between $600 million and $620 million.
Guardant Health Inc. (GH) gained 19.29% in extended trading, moving from $72.27 to $86.21. The company's third-quarter revenue reached $265.2 million, up 39% from the prior year. While it reported a net loss of $92.7 million, this was narrower than the $107.8 million loss in the same period last year. Guardant also raised its full-year 2025 revenue guidance to a range of $965 million to $970 million, up from a previous forecast of $915 million to $925 million.
Align Technology, Inc. (ALGN) saw its shares jump 15.15% after hours, closing at $131.91 before rallying to $151.89. The company posted third-quarter net income of $56.8 million, or $0.78 per share, with non-GAAP net income of $189.0 million, or $2.61 per share. Although revenue dipped slightly from the previous quarter, it still marked a 1.8% increase year-over-year. Align expects fourth-quarter revenue to rise sequentially, guiding to a range of $1.025 billion to $1.045 billion.
Neumora Therapeutics, Inc. (NMRA) also made a strong move, climbing 23.20% to $3.08 in overnight trading despite no accompanying news. The stock had closed the regular session at $2.50, down 3.47%, before reversing course in the after-hours market.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.